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Introduction:
Heat shock protein 27 (HSP27) is an intracellular molecular chaperone that is expressed in response to the exposure of cells to environmental stressors (1) and increases the ability of cells to overcome environmental stress (2) . HSPs modify several aspects of cell function, including differentiation, apoptosis, and the repair and refolding of denatured proteins (3).
They are associated with cell exposure to a wide variety of environmental stresses including high temperature, viral infection, oxidative stress, ischemia, heavy metals, ultraviolet irradiation, and reactive oxygen species (ROS) (4).
HSPs are highly immunogenic, and it is believed that an autoimmune response to HSPs contributes to rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus erythematosus (5, 6) , and diabetes mellitus (1). There are several HSP families of proteins:
HSPH (former name HSP110), HSPC (HSP90), HSPA (HSP70), HSPD/E (HSP60/HSP10), CCT (TRiC), DNAJ (HSP40), and HSPB (small HSP or sHSP) including HSP27 (7) . HSP27
is a member of the sHSP family of proteins (8) , and high serum titers of this protein have been reported in individuals with cardiovascular disease (CVD) (9) . HSP27 has been suggested as a marker of inflammation (10), and immune response to HSPs may contribute to the progression of atherosclerosis. Anti-HSP27 antibodies titers were increased during atherogenesis (9, 11) . Serum anti-HSP27 antibody titers have been suggested to predict outcomes in cancer and may help to identify individuals at high risk of CVD (1).
There is growing evidence of a relationship between HSPs and inflammatory diseases, including CVD. Most studies have focused on HSP/anti-HSP60, 65, and 70, although recent data support the role of HSP/anti-HSP27 in CVD, which is the leading cause of death worldwide (9, 12, 13 ).
We have previously demonstrated an association between hypertension and serum anti-HSP27 antibody levels; however, the association with diabetes mellitus and smoking status ACCEPTED MANUSCRIPT
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was not statistically significant for a sample of 168 patients. Moreover, we previously reported a relationship between anti-HSP27 antibody levels and risk of myocardial infarction (13). The present study aimed to investigate serum anti-HSP27 antibody levels and determine factors affecting it in a large population. and all the subjects provided written informed consent to participate in the study.
Materials and methods:
Population
Anthropometric measurements
Anthropometric parameters including height, body weight, waist circumference, and hip circumference were measured for all participants as described previously (15). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). In addition, we collected information about the socioeconomic status of our subjects. The subjects were divided into three subgroups: obese (BMI≥30 kg/m 2 ), overweight (30>BMI≥25 kg/m 2 ), and normal weight (BMI<25 kg/m 2 ) (14, 15).
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Fasting blood glucose (FBG) levels were measured as described before (14-15) using the BT-3000 auto-analyzer machine (Biotechnica, Rome, Italy). High-sensitivity C-reactive protein (hs-CRP) was measured by a PEG-enhanced immunoturbidimetry method using an Alycon analyzer (ABBOTT, Chicago, IL, USA).
Serum anti-HSP27 antibody titer measurements
Anti-HSP27 antibody titers were determined in serum as previously described (16, 17). (subtracting the absorbance of uncoated wells from the antigen-coated wells for each sample), the results were expressed in optical density units.
Statistical analysis
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A C C E P T E D M A N U S C R I P T Data were analyzed using SPSS software (version 11.5). Kruskal-Wallis test (for more than two groups). Spearman correlation was used to investigate the relationship between the anti-HSP antibody titers and atherosclerosis risk factors including age, serum total cholesterol, hs-CRP, triglyceride, HDL-C, LDL-C, cholesterol/HDL-C ratio, BMI, systolic and diastolic blood pressure, FBG, and waist and hip circumferences, height, and waist/hip ratio. We determined the factors that were significantly related to serum HSP27 antibody titers using stepwise multiple regression. A two-sided P<0.05 was considered significant.
Results
Effect of gender, age, and smoking status on serum anti-HSP27 antibody levels
As shown in Table 1 , age, FBG, waist/hip ratio, LDL-C, serum triglycerides, systolic blood pressure, and presence of other CVD risk factors including diabetes mellitus and hypertension (P>0.05) were not significantly different between the groups. However, women had a significantly higher BMI, waist and hip circumferences, HDL-C, and hs-CRP (Table 1) .
Serum anti-HSP27 antibody levels did not differ between men and women. Similar results were also observed after dividing the participants in to age cohorts: 35-44, 45-54, and 55-65 years ( Table 2) .
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Effect of BMI on serum anti-HSP27 antibody level
Obese subjects had significantly higher BMI, waist/hip ratio, FBG, serum triglyceride, hs-CRP, SBP/DBP, and LDL-C; HDL-C levels were lower in obese than in nonobese subjects (P<0.05). Hypertension and dyslipidemia were more common in the obese subjects than in the nonobese subjects (Table 3) . Serum anti-HSP27 antibody titer was significantly higher in the obese subjects than in the nonobese subjects (P=0.046, Table 5 ). After adjustment, the differences between the groups remained significant (BMI: β=0.036, P=0.037).
Effect of socioeconomic status on serum anti-HSP27 antibody levels
Subjects were divided into six subgroups of educational attainment: primary school, secondary school, high school, diploma, bachelor or postgraduate, and PhD or MD. Serum anti-HSP27 antibody titers were not significantly different between the groups. Similar results were observed for the effect of employment status on anti-HSP27 antibody levels (Table 4 -5).
Effect of atherosclerosis risk factors on anti-HSP27 antibody levels
Associations between anti-HSP27 antibody levels and atherosclerosis risk factors were assessed by general linear model analysis as the dependent variable (anti-HSP27) is quantitative and independent variables are both qualitative and quantitative. These results showed that age, BMI, waist/hip ratio, triglycerides, cholesterol, hs-CRP, hyperlipidemia, and hypertension were positively associated with serum anti-HSP27 antibody titers (Table 6 ).
Discussion
To the best of our knowledge, this is the first study evaluating the effect of demographic characteristics and socioeconomic status with respect to serum anti-HSP27 antibody titers.
We found that obese subjects had significantly higher anti-HSP27 antibody titers than the nonobese group, which is in agreement with our previous report (16). Therefore, our recent data suggest that this biological marker can be used as a novel risk biomarker for CVDs.
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There is growing body of data suggesting the important role of this marker in CAD and stroke (12-13, 16-18). In the present study, we also investigated its relationship with age. Our data showed that serum anti-HSP27 antibody titer did not differ with gender, which is consistent with the results of Zilaee et al, who observed no significant relationship between gender and antibody titers to HSP27 and 60 (18). Moreover, Rea et al, in a study of 60 individuals aged between 20 and 96 years, showed that the anti-HSP70 antibody levels increased significantly with age (19). Another study also reported that serum anti-HSP27
antibody levels increased with age, and it was associated with hypertension (20). We found a significant increase in anti-HSP27 antibody levels with respect to age in the male subgroup, which is in agreement with a previous report (20). Moreover, we explored the effect of smoking status on serum anti-HSP27 antibody titers. However, no statistically significant differences were observed between groups, which is consistent with our previous data (21).
There is accumulating evidence showing the association of inflammatory markers such as CRP, TNF-α, and IL-6 with obesity (22). Our previous data revealed the association of body mass and antibody titers to HSP60, 65, and 70 in 170 healthy Caucasians (23). In the current study, we showed for the first time the important role of serum anti-HSP27 antibody titers as a biomarker in obese subjects. Previous studies have shown that serum anti-HSP27 antibody levels may reflect inflammatory status (10, 23). The role of anti-HSP antibody titers has been shown during the process of atherosclerosis (9, 11), and the high levels of anti-HSP27
antibodies in obese subjects suggest that an immune response to HSPs contributes to the progression of atherosclerosis in these subjects.
The effect of socioeconomic status on serum anti-HSP27 antibody titers was studied in our population, although no statistically significant relationship was observed for these parameters. Victora et al (2007) showed no association between serum anti-HSP60 antibody
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A major strength of the present study is that it was performed in a large number of subjects, and the effect of demographic, biochemical, and socioeconomic status of the population on the anti-HSP27 antibody levels was studied. Moreover, this is the first study showing the effect of obesity, a risk factor for CVD, on the level of serum anti-HSP27 antibody titers. 
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Anti-HSP27 (OD)
BMI, body mass index; FBG, fasting blood sugar; WC, waist circumferences; HC, hip circumferences; WHR, waist/hip ratio; LDL-C, low-density lipoprotein cholesterol, HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; hs-CRP, high sensitivity c-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure. Diabetes was defined as fasting blood glucose of ≥126 mg/L. Hypertension was defined as a SBP ≥140 mmHg and a DBP ≥90 mmHg. Hyperlipidaemia was defined as a total cholesterol (TC) ≥5.2 mmol/l (200 mg/dl), triglycerides (TG) ≥1.5 mmol/l (150 mg/dl), and HDL-C <0.9 mmol/l (40 mg/dl) (for men), and <1.29 mmol/l (50 mg/dl)(for women). Values are expressed as mean±SD, and interquartile range or median and Mann-Whitney test were used for normality and non-normality distributed data, respectively.
